RESUMO
La medicina y la tecnología están en continua evolución. La pandemia ha acelerado el desarrollo de la digitalización del sector sanitario y, en concreto, de la telemedicina. Mediante una revisión bibliográfica estructurada siguiendo la metodología Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA), en este trabajo se definen los conceptos relacionados con la telemedicina, su aplicación y el contexto regulatorio legal. Con esta información, se proponen unas recomendaciones y códigos de buenas prácticas para su implementación efectiva en el ámbito de la Hepatología (AU)
Assuntos
Humanos , Gastroenterologia/tendências , Telemedicina/tendências , Consulta Remota/tendênciasRESUMO
Future costs are not usually included in economic evaluations. The aim of this study was to assess the extent of published economic analyses that incorporate future costs. A systematic review was conducted of economic analyses published from 2008 to 2013 in three general health economics journals: PharmacoEconomics, Value in Health and the European Journal of Health Economics. A total of 192 articles met the inclusion criteria, 94 of them (49.0%) incorporated future related medical costs, 9 (4.2%) also included future unrelated medical costs and none of them included future nonmedical costs. The percentage of articles including future costs increased from 2008 (30.8%) to 2013 (70.8%), and no differences were detected between the three journals. All relevant costs for the perspective considered should be included in economic evaluations, including related or unrelated, direct or indirect future costs. It is also advisable that pharmacoEconomic guidelines are adapted in this sense.
Assuntos
Farmacoeconomia/tendências , Custos de Cuidados de Saúde/tendências , Publicações Periódicas como Assunto/estatística & dados numéricos , Custos e Análise de Custo/métodos , Atenção à Saúde/economia , HumanosRESUMO
BACKGROUND/AIMS: Chronic Hepatitis C virus (HCV) infection is common and often produces a progressive disease. Some studies suggest that HCV related complications will increase in the future. Our aim was to estimate the future morbidity, mortality and costs of chronic HCV infection in a cohort of patients infected by HCV and to evaluate the impact of HCV therapy. METHODS: A mathematical model was used to project over the next 30 years, the HCV related complications and costs in a cohort of 419,895 infected patients representing the HCV infected population in Spain. The impact of HCV therapy with peginterferon and ribavirin in this population was also projected. RESULTS: A gradual decline in the infected population is expected in the future, however, the proportion of patients with cirrhosis will increase by up to 14% and morbidity associated with HCV infection by up to 10% by the year 2030 with a subsequent increment in HCV related costs. However, treating from 10 to 50% of the HCV population will result in a reduction of 6 and 26% in morbidity and 4 and 20% in mortality, respectively. The cost per year of life gained ranges from 6078 for a 29-year-old patient to 8911 for a 59-year-old patient. CONCLUSIONS: In the future, HCV infection mortality, morbidity and associated costs will increase. Treatment of the chronic HCV infected population can eradicate the infection, increase patients' survival and reduce the need for liver transplantation, making this a cost-effective strategy.
